Botanix Announces Expanded Payer Coverage for Sofdra
11/14/2024
Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis.
According to a press release from Botanix, Ascent represents approximately 65 million (or nearly 40%) of US commercial lives. Sofdra will be covered in line with tarted patient access restrictions. The coverage is on top of existing Payer coverage that brings the total to more than 110 million commercial lives.
Sofdra is the first and only FDA-approved chemical entity for the treatment of primary axillary hyperhidrosis, a condition that impacts about 10 million patients in the US.
Source: Botanix press release. November 14, 2024.